Helix BioPharma Corp
Helix BioPharma Corp., based in Toronto, Ontario, is a clinical-stage oncology company dedicated to developing novel therapies aimed at challenging hard-to-treat cancers. With a growing portfolio of drug candidates, the company focuses on precision medicine using its proprietary platform of bio-conjugates designed to target solid tumors that over-express CEACAM6.
The company's lead candidate, Tumour Defence Breaker™ L-DOS47, is an innovative antibody-enzyme conjugate that enhances the immune system's ability to combat tumors, standing as a potential game-changer in oncology treatment. Helix BioPharma boasts a team of experienced professionals who are committed to advancing their clinical programs and achieving significant milestones in cancer therapy.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.